In May, Rib-X postponed its $80m initial public offering, according to Nasdaq OMX.
Rib-X Pharmaceuticals, a US-based antibiotics developer backed by drugs companies GlaxoSmithKline (GSK) and AstraZeneca’s corporate venturing units, has raised $18.7m in the first tranche of a planned $67.5m series two preferred stock financing.
Vatera Healthcare Partners, a a venture capital firm established by Michael Jaharis, founder of Kos Pharmaceuticals, a specialty pharmaceutical company sold to Abbott Laboratories in 2006 for $4.2bn, and of Key Pharmaceuticals, a specialty pharmaceutical company merged with Schering-Plough in 1986 for $836m, led the round as a new investor,…
